Article Highlights•B-type natriuretic peptide (BNP)/N-terminal pro-BNP (NT-proBNP) levels are often elevated in patients with sepsis.•The optimal cutoffs for mortality prediction remain incompletely understood.•BNP and NT-proBNP levels of 622 pg/mL and 4000 pg/mL predicted short-term mortality.

Sepsis continues to be a leading cause of mortality and morbidity in the United States and accounts for nearly \$17 billion in annual health care expenditure.[@bib1] Sepsis is associated with multiorgan dysfunction, prominent among which are injury and dysfunction of the cardiovascular and renal systems.[@bib2]^,^[@bib3] Cardiac dysfunction in patients with sepsis can manifest as a combination of circulatory failure, septic cardiomyopathy, and myocardial injury and refractory shock.[@bib1]^,^[@bib4], [@bib5], [@bib6], [@bib7], [@bib8], [@bib9], [@bib10], [@bib11], [@bib12], [@bib13] With the development of sensitive laboratory technology, there is a renewed interest in the use of biomarkers for early and targeted treatment of cardiac dysfunction in patients with sepsis and septic shock.[@bib1] Cardiac biomarkers, such as cardiac troponin T, troponin I, B-type natriuretic peptide (BNP), and N-terminal pro-BNP (NT-proBNP), have been studied previously in patients with sepsis and septic shock.[@bib14]^,^[@bib15] Prior studies have associated cardiac troponins with the degree of myocardial injury, hypotension, cardiomyopathy, and extent of vasopressor support.[@bib1]^,^[@bib16] We previously reported that admission troponin T, but not serial troponin T, levels have been associated with in-hospital and long-term mortality in patients with sepsis.[@bib1] In a 2013 meta-analysis evaluating troponins, Bessière et al[@bib14] documented that troponin levels correlated with shock severity and short-term and long-term mortality.

B-type natriuretic peptide is synthesized as a precursor protein (proBNP) in response to increased myocardial wall stress due to volume or pressure overload. Most of it is subsequently cleaved into active peptide BNP 1-32 and biologically inert NT-proBNP.[@bib17] Typically, NT-proBNP levels are higher than BNP levels.[@bib17]^,^[@bib18] A 2012 meta-analysis found BNP as a predictor of mortality in patients with sepsis with pooled sensitivity and specificity of 79% and 60%; there was significant heterogeneity (*I*^*2*^=64%) among the evaluated studies.[@bib15] In this systematic analysis, BNP assays, clinical end points, and vasopressor use varied markedly among the enrolled studies.[@bib15] In other critically ill patients with pulmonary embolism, chronic obstructive pulmonary disease, and congestive heart failure, BNP has been strongly associated with clinical outcomes and has been incorporated into risk stratification.[@bib19], [@bib20], [@bib21] In patients with sepsis, however, there are conflicting data on the role of BNP/NT-proBNP as a risk-stratification and prognostication tool. Some investigators have considered BNP as a marker of severity, whereas others have reported it as an independent prognostic test. In light of the multiple recent studies with contrasting results, we sought to undertake a systematic review and meta-analysis of natriuretic peptide levels in the prognostication of patients with sepsis and septic shock.[@bib22], [@bib23], [@bib24], [@bib25], [@bib26], [@bib27], [@bib28], [@bib29] These discrepant results may be partly due to the heterogeneity of sepsis, differences in timing of BNP measurement, types of assays used, small sample sizes, and lack of control for septic cardiomyopathy.[@bib5]^,^[@bib8]^,^[@bib18]^,^[@bib30] The primary outcome was to develop a summative value of BNP and NT-proBNP that is associated with mortality in this population.

Patients and Methods {#sec1}
====================

Data: Sources, Strategies, and Inclusion {#sec1.1}
----------------------------------------

We conducted a comprehensive search of several databases for articles published from January 1, 2000, to September 5, 2017. The databases included Ovid MEDLINE Epub Ahead of Print, Ovid MEDLINE In-Process & Other Non-Indexed Citations, Ovid MEDLINE, Ovid EMBASE, Ovid Cochrane Central Register of Controlled Trials, Ovid Cochrane Database of Systematic Reviews, and Scopus. The search strategy was designed and conducted by a medical librarian with input from the authors. Controlled vocabulary supplemented with keywords was used to search for mortality prediction in patients with sepsis using BNP or NT-proBNP in adults ([Supplemental Appendix 1](#appsec1){ref-type="sec"}, available online at <http://mcpiqojournal.org>). The abstracts were screened by 2 independent reviewers (Saarwaani Vallabhajosyula, Shashaank Vallabhajosyula). All references of included studies were evaluated for additional studies. Study inclusion was based on the consensus of the 2 reviewers. A third independent reviewer (P.R.S.) served as the referee in cases of disagreement between the first 2 reviewers. The search strategy and reporting were performed following the Strengthening the Reporting of Observational Studies in Epidemiology guidelines.[@bib31] This protocol has not been registered previously in available systematic review databases. Corresponding authors of included studies were not contacted for patient-level data, and all analyses performed in this study were based on the summative publicly available data. A subsequent updated search was performed between September 5, 2017, and June 25, 2019, and the results are presented in [Supplemental Appendix 2](#appsec1){ref-type="sec"} and [Supplemental Table 1](#appsec1){ref-type="sec"} (available online at <http://mcpiqojournal.org>). These studies were not included in the final meta-analysis for this study.

English-language studies evaluating adult patients (\>18 years) with sepsis, severe sepsis, or septic shock defined using either the 2001 International Sepsis Definitions[@bib32] or Sepsis-3 (Third International Consensus Definitions for Sepsis and Septic Shock)[@bib33] criteria were included. Human studies of case-control, cohort, and randomized trial study designs were included. Short-term mortality was defined as intensive care unit mortality, in-hospital mortality, 28-day mortality, or 30-day mortality. In studies evaluating unselected critically ill patients, only studies for which a 2 × 2 table could be constructed between BNP/NT-proBNP levels and mortality were included. Abstracts that were not published in full text were excluded. Studies designed as case reports/series, systematic or narrative reviews, pediatric or animal studies, and studies without relevant outcomes were excluded. If multiple studies were published by the same group of authors over the same study duration, only a single study with relevant outcomes was included. Data abstracted included study year, population, location, type of study, comorbidities, and clinical outcomes. The clinical outcome of interest was BNP/NT-proBNP level that was associated with mortality.

Evidence Synthesis {#sec1.2}
------------------

The methodological quality of the included studies was assessed using the Newcastle-Ottawa Scale for nonrandomized studies by 2 independent reviewers (Saarwaani Vallabhajosyula, Shashaank Vallabhajosyula) ([Supplemental Table 2](#appsec1){ref-type="sec"}, available online at <http://mcpiqojournal.org>) (Cohen κ statistic for agreement between reviewers, 0.82).[@bib34] This scale involves evaluation based on 3 areas: (1) selection of the study groups, (2) comparability among groups, and (3) the assessment of outcome between the groups. We extracted or calculated the average values of BNP and NT-proBNP tests for those who survived and those who died. We then estimated the receiver operating characteristic curve (ROC) using the parametric ROC regression model proposed by Alonzo and Pepe.[@bib35] Each study was weighted by the number of patients. We used the area under the ROC (AUROC) as a measure of test performance for mortality prediction. Optimal sensitivity (Sn) and specificity (Sp) and corresponding cutoffs were estimated using the Youden index.[@bib36] Multiple subgroup analyses were performed to confirm the primary findings and to understand the predictive capacity of BNP/NT-proBNP. Subgroups were stratified by timing of BNP/NT-proBNP measurement (≤24 hours/\>24 hours after hospital admission), study era (≤2010/\>2010), studies performed in the United States and Europe vs other countries, and studies evaluating all types of sepsis vs only severe sepsis and septic shock. All statistical analyses were conducted using Stata statistical software, version 15.1 (StataCorp).

Results {#sec2}
=======

A total of 452 unique studies were identified by the initial search strategy. Abstracts and subsequently full texts of selected articles were screened, and 35 studies, with a total of 3508 patients, were selected for data extraction ([Figure 1](#fig1){ref-type="fig"}). All the studies were of moderate methodological quality. Detailed study characteristics and populations are highlighted in [Table 1](#tbl1){ref-type="table"}.[@bib24]^,^[@bib25]^,^[@bib27]^,^[@bib28]^,^[@bib37], [@bib38], [@bib39], [@bib40], [@bib41], [@bib42], [@bib43], [@bib44], [@bib45], [@bib46], [@bib47], [@bib48], [@bib49], [@bib50], [@bib51], [@bib52], [@bib53], [@bib54], [@bib55], [@bib56], [@bib57], [@bib58], [@bib59], [@bib60], [@bib61], [@bib62], [@bib63], [@bib64], [@bib65], [@bib66], [@bib67], [@bib68] All except 2 studies were prospective observational studies, and only 2 studies were conducted at multiple sites. Three studies were conducted in the emergency department, while the rest were conducted in intensive care units. All studies used the 2001 definition for sepsis and septic shock and used varying inclusion and exclusion criteria as detailed in [Table 1](#tbl1){ref-type="table"}.[@bib32] Concomitant heart failure, cor pulmonale, valvular heart disease, acute coronary syndrome, intracranial hemorrhage, and chronic kidney disease were the most common reasons for exclusion of patients across the 36 studies. The median age across the studies varied from 51 to 75 years, and 12% to 74% of patients were male. Most studies measured BNP/NT-proBNP at emergency department or intensive care unit admission or within the first 24 hours after admission ([Table 2](#tbl2){ref-type="table"}).Figure 1PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) diagram of search strategy.Table 1Study CharacteristicsNatriuretic peptideReference. yearCountrySettingStudy designInclusion criteriaExclusion criteriaBNPCharpentier et al,[@bib37] 2004FranceSingle ICU & centerProspective cohortSepsisPregnancy, CHF, HTN, LVH, CP, COPD, CKDBNPCuthbertson et al,[@bib28] 2005ScotlandSingle ICU & centerProspective cohortSepsisSevere neurologic injuryBNPIssa et al,[@bib38] 2008BrazilSingle ICU & centerProspective cohortSevere sepsis and septic shockICH, hemodialysis, heart disease, ACSBNPKlouche et al,[@bib39] 2014FranceSingle ICU & centerProspective cohortSevere sepsis and septic shockPregnancy, age \<18 y, CHF, RWMA, CKD, acute VTEBNPLi et al,[@bib40] 2016ChinaSingle ICU & centerProspective cohortSevere sepsis and septic shockAge \<18 y, CHF, CKD, ICU stay \<24 h, immunosuppressionBNPLiu et al,[@bib41] 2016ChinaSingle ICU & centerProspective cohortSurgical sepsisTransplant, cardiac surgery, immunosuppressionBNPMcCormack et al,[@bib42] 2016USSingle ED & centerRetrospective cohortSepsisNABNPMcLean et al,[@bib43] 2007AustraliaSingle ICU & centerProspective cohortSevere sepsis and septic shockNegative cultures, poor echo windowsBNPPapanikolaou et al,[@bib44] 2014GreeceSingle ICU & centerProspective cohortSevere sepsis/septic shock, IMVCHF, CKD, PH, CNS disease, inotropes useBNPPost et al,[@bib45] 2008GermanySingle ICU & centerProspective cohortSeptic shockCHFBNPRyoo et al,[@bib46] 2015KoreaSingle ICU & centerProspective cohortSeptic shockMI, CHFBNPSalim et al,[@bib47] 2015EgyptSingle ICU & centerProspective cohortSepsis, severe sepsis, septic shockCoronary artery disease, CHF, atrial fibrillationBNPShor et al,[@bib48] 2006IsraelSingle ICU & centerProspective cohortSepsis, septic shockCHF, ACS, CKD, VTE, COPD, cancerBNPSturgess et al,[@bib49] 2010AustraliaSingle ICU & centerProspective cohortSeptic shockVHDBNPTurner et al,[@bib50] 2011USSingle ICU & centerProspective cohortSepsis, severe sepsis, septic shockOrgan transplantBNPYucel et al,[@bib24] 2008TurkeySingle ICU & centerProspective cohortSepsisCardiogenic shock, trauma, burnsBNPZhang et al,[@bib51] 2012ChinaSingle ICU & centerProspective cohortSepsisCKD, AKINT-proBNPBalcan et al,[@bib52] 2016TurkeySingle ICU & centerProspective cohortSepsisNANT-proBNPBalcan et al,[@bib53] 2015TurkeySingle ICU & centerRetrospective cohortSepsisCHF, CKDNT-proBNPBrueckmann et al,[@bib54] 2005GermanyMultiple ICUs & centersProspective cohortSepsisDCM, CP, VHD, CKD, ACSNT-proBNPCheng et al,[@bib55] 2015ChinaSingle ICU & centerProspective cohortSepsisAge \<65 y, ICU stay \<4 h, ACS, VHD, COPD, CKD, immunosuppressionNT-proBNPGarcía Villalba et al,[@bib56] 2017SpainSingle ICU & centerProspective cohortSepsisNANT-proBNPGuaricci et al,[@bib57] 2015ItalySingle ICU & centerProspective cohortSepsisLVEF \<50%, DCM, CP, VHD, CKD, TBI, death \<72 hNT-proBNPJu et al,[@bib58] 2012ChinaSingle ICU & centerProspective cohortSepsisPregnancy, CHF, age \<18 y, CKDNT-proBNPLandesberg et al,[@bib59] 2012IsraelSingle ICU & centerProspective cohortSevere sepsis and septic shockVHD, RWMA, MI, poor echo imagesNT-proBNPLi et al,[@bib60] 2014ChinaSingle ICU & centerProspective cohortSepsisAge \<18 y, cancer, ACS, CKD, ICU stay \<24 hNT-proBNPMokart et al,[@bib61] 2007FranceSingle ICU & centerProspective cohortSepsisCHF, CKD, COPD, brain disordersNT-proBNPPark et al,[@bib62] 2011KoreaSingle ICU & centerProspective cohortSeptic shock, ARDSCNS disease, pregnancy, MI, CHF, CKD, VTENT-proBNPRoch et al,[@bib25] 2005FranceSingle ICU & centerProspective cohortSeptic shock, IMVCHF, COPD, CKD, CNS diseaseNT-proBNPSasko et al,[@bib63] 2015GermanySingle ICU & centerProspective cohortSeptic shockARDSNT-proBNPSekino et al,[@bib64] 2017JapanSingle ICU & centerProspective cohortSeptic shockIntestinal ischemia/resectionNT-proBNPSturgess et al,[@bib27] 2010AustraliaSingle ICU & centerProspective cohortSeptic shockVHDNT-proBNPVarpula et al,[@bib65] 2007FinlandMultiple ICUs & centersProspective cohortSepsis, septic shockCHF, CAD, prior MI, HTN, diabetes mellitusNT-proBNPWang et al,[@bib66] 2016ChinaSingle ICU & centerProspective cohortSepsisACS, CHF, CAD, hepatic/renal failureNT-proBNPWang et al,[@bib67] 2015ChinaSingle ICU & centerProspective cohortSeptic shockStay \<72 h, prior MI, CNS diseaseNT-proBNPZhang et al,[@bib68] 2013ChinaSingle ED & centerProspective cohortSepsisCHF, DCM, VHD, ACS, CKD[^1]Table 2Study Population and Natriuretic Peptide Characteristics[a](#tbl2fna){ref-type="table-fn"}Natriuretic peptideAuthor/YearTotal patientsAge (years)\
*(Mean ± SD/Median \[IQR\])*Male sex\
*N (%)*BNP/NT-proBNP assayBNP/NT-proBNP timingBNPCharpentier 20043456 (2.7)16 (47.1)Shionora-BNP immunoradiometric assayDays 1, 2, 3, 4, 8BNPCuthbertson 20053566 (55-74)20 (57)Bayer ADVIA ImmunoassayICU admissionBNPIssa 20082351.3 (18.6)14 (60.9)Microparticle Immunoassay (MEIA-Abbott)ICU admissionBNPKlouche 20144760 (16)27 (57.5)Immunochemilumiscent Access 2 analyzerDay 5BNPLi 201684NA56 (66.7)Elecsys 2010 Roche DiagnosticsDays 1, 3, 5BNPLiu 201615661 (40-76)100 (64.4)NAICU admissionBNPMcCormack 201637NANANAED admissionBNPMcLean 200740NANATriage BNP detectorDays 1-10BNPPapanikolaou 201442NA26Biosite Triage BNP meterDays 1, 2, 3, 4, 5BNPPost 20089365 (53-73.5)51 (55)Biosite Triage BNP meterDay 5BNPRyoo 201529063.9 (13)170 (58.6)ADVIA Centaur, Bayer DiagnosticsICU admissionBNPSalim 201540NA22Enzyme immunoassayDays 1, 3BNPShor 20062179.3 (9.15)NAAxsym Abott immunoassayICU admissionBNPSturgess 20102153.5 (19.6)13 (61.9)Biosite Triage BNP analyzer\<72 hoursBNPTurner 201123159 (3)100 (43)\-\-\-\-\--BNPYucel 200840NANAShionora-BNP assay, Cisbio InternationalDays 1, 2, 28BNPZhang 20127359 (16)43 (64.2)Biosite Triage BNP analyzerICU admissionNT-proBNPBalcan 20164866.8 (17.9)74 (52.5)NAICU admissionNT-proBNPBalcan 201514161.5 (12.4)20 (42)NA\<24 hoursNT-proBNPBrueckmann 20055755 (16.3)42 (74)Biozol, Enzyme ImmunoassayDay 2NT-proBNPCheng 201543074.15 (14)219 (50.8)NAICU admissionNT-proBNPGarcia 201717473 (16)102 (58.6)LOCI Chemiluminescent ImmunoassayICU admissionNT-proBNPGuaricci 20154064 (48.75-72)22 (55)Biozol, Enzyme Immunoassay6, 72 hoursNT-proBNPJu 201210065.97 (13.95)74 (74)Cobase e411, Roche DiagnosticsICU admissionNT-proBNPLandesberg 2012262NA159 (60.7)Elecsys 2010 Roche DiagnosticsICU admissionNT-proBNPLi 201410263 (21)49 (48)Elecsys 2010 Roche DiagnosticsDays 1, 3, 5NT-proBNPMokart 20075156 (50-68)32 (62)Roche Elecsys 2010Day 1, 2NT-proBNPPark 20114964 (15)28 (57.1)Elecsys 2010 Roche DiagnosticsDays 1, 2, 3NT-proBNPRoch 20053963 (12)NAElecsys 2010 Roche DiagnosticsICU admissionNT-proBNPSasko 20155271.4 (8.5)31 (59.6)NAICU admissionNT-proBNPSekino 20175771 (62-79)35 (61)Elecsys 2010 Roche DiagnosticsICU admissionNT-proBNPSturgess 20102153.5 (19.6)13 (61.9)Elecsys 2010 Roche Diagnostics\<72 hoursNT-proBNPVarpula 200725459 (15)175 (69)Elecsys 2010 Roche DiagnosticsICU admissionNT-proBNPWang 201638NA21Roche Diagnostics GmbHDays 1, 3, 7NT-proBNPWang 201511572.9 (7.6)NAVIDAS automated test, BiomerieuxICU admissionNT-proBNPZhang 201317154.6 (9.8)101 (59.1)Elecsys 2010 Roche DiagnosticsED admission[^2]

Absolute mortality rate was not reported in one study.[@bib42] Cumulative short-term mortality was 34.2% (1188/3471) in the 35 studies that reported mortality rates. Detailed mortality rates and BNP/NT-proBNP values based on the vital status of patients in each study are reported in [Table 3](#tbl3){ref-type="table"}. As noted in [Table 3](#tbl3){ref-type="table"}, studies reported varying cutoffs of BNP/NT-proBNP in estimating mortality in patients with sepsis and septic shock. These cutoffs had varying AUROCs of 0.62 to 0.99 in the studies that reported these statistics. Using the parametric ROC regression model, we estimated the AUROC for BNP and NT-proBNP individually ([Figures 2](#fig2){ref-type="fig"}A and B). A BNP value of 622 pg/mL (to convert to ng/L, multiply by 1.0) had the greatest discrimination for short-term mortality prediction in patients with sepsis---Sn, 0.695 (95% CI, 0.659-0.729); Sp, 0.907 (95% CI, 0.810-1.003); and AUROC, 0.766 (95% CI, 0.734-0.797). An NT-proBNP value of 4000 pg/mL (1 pg/mL = 0.118 pmol/L) had the greatest discrimination for short-term mortality prediction in patients with sepsis---Sn, 0.728 (95% CI, 0.703-0.753); Sp, 0.789 (95% CI, 0.710-0.867); and AUROC, 0.787 (95% CI, 0.766-0.809). In the prespecified subgroup analyses, the BNP cutoff had greater discrimination for in-hospital mortality when measured 24 hours or less after hospital admission---AUROC, 0.920 (95% CI, 0.889-0.951); Sn, 0.779 (95% CI, 0.723-0.834); and Sp, 0.986 (95% CI, 0.966-1.000), as compared to more than 24 hours after hospital admission---AUROC, 0.725 (95% CI, 0.684-0.766); Sn, 0.644 (95% CI, 0.599-0.688); and Sp, 0.964 (95% CI, 0.892-1.000). Because only a limited number of studies measured NT-proBNP during the first 24 hours, this subgroup analysis was restricted to more than 24 hours after hospital admission. The NT-proBNP values measured at more than 24 hours after hospital admission had an AUROC of 0.790 (95% CI, 0.768-0.812), Sn of 0.736 (95% CI, 0.711-0.761), and Sp of 0.773 (95% CI, 0.690-0.857). When stratified by year, BNP (≤2010---AUROC of 0.77 \[95% CI, 0.73-0.80\], Sn of 0.67 \[95% CI, 0.58-0.75\], and Sp of 0.59 \[95% CI, 0.50-0.67\]; \>2010---AUROC of 0.82 \[95% CI, 0.78-0.85\], Sn of 0.76 \[95% CI, 0.73-0.80\], and Sp 0.93 \[95% CI, 0.82-1.00\]) and NT-proBNP (≤2010---AUROC of 0.78 \[95% CI, 0.63-0.84\], Sn of 0.64 \[95% CI, 0.57-0.71\], and Sp of 0.99 \[95% CI, 0.99-1.00\]; \>2010---AUROC of 0.81 \[95% CI, 0.78-0.83\], Sn of 0.73 \[95% CI, 0.70-0.76\], and Sp 0.83 \[95% CI, 0.76-0.89\]) had greater accuracy for studies performed after 2010. When restricted to only patients with severe sepsis/septic shock, BNP had higher discrimination (severe sepsis/septic shock---AUROC of 0.79 \[95% CI, 0.0.75-0.84\], Sn of 0.70 \[95% CI, 0.65-0.75\], and Sp of 0.83 \[95% CI, 0.73-0.94\]; all sepsis---AUROC of 0.77 \[95% CI, 0.0.72-0.82\], Sn of 0.71 \[95% CI, 0.66-0.76\], and Sp of 0.92 \[95% CI, 0.74-1.00\]), but NT-proBNP had lower discrimination (severe sepsis/septic shock---AUROC of 0.80 \[95% CI, 0.77-0.84\], Sn of 0.66 \[95% CI, 0.62-0.71\], and Sp of 0.93 \[95% CI, 0.87-0.98\]; all sepsis---AUROC of 0.84 \[95% CI, 0.82-0.87\], Sn of 0.74 \[95% CI, 0.70-0.77\], and Sp of 0.87 \[95% CI, 0.82-0.87\]). When stratified by country, studies performed in the United States and Europe had greater accuracy for mortality prediction for both BNP (United States/Europe---AUROC of 0.82 \[95% CI, 0.77-0.87\], Sn of 0.70 \[95% CI, 0.64-0.77\], and Sp of 0.86 \[95% CI, 0.77-0.95\]; other countries---AUROC of 0.75 \[95% CI, 0.71-0.79\], Sn of 0.70 \[95% CI, 0.65-0.74\], and Sp of 0.92 \[95% CI, 0.75-1.00\]) and NT-proBNP (United States/Europe---AUROC of 0.83 \[95% CI, 0.78-0.87\], Sn of 0.70 \[95% CI, 0.65-76\], and Sp of 0.98 \[95% CI, 0.94-1.00\]; other countries---AUROC of 0.78 \[95% CI, 0.76-0.81\], Sn of 0.71 \[95% CI, 0.68-0.74\], and Sp of 0.79 \[95% CI, 0.71-0.87\]).Table 3Natriuretic Peptides and MortalityNatriuretic peptideReference, yearTotal patientsPatients alivePatients deadMortality predictionNo.Mean ± SD or median (IQR)No.Mean ± SD or median (IQR)CutoffSn/Sp (%)AUROCBNPCharpentier et al,[@bib37] 20043424181±4610905±24619070/670.66BNPCuthbertson et al,[@bib28] 20053525651 (242-1023)10377 (85-683)100NANABNPIssa et al,[@bib38] 2008238173.8±1.815199.5±2.7NANANABNPKlouche et al,[@bib39] 20144734836±859132605±1957NANANABNPLi et al,[@bib40] 20168440216 (110-689)44456.7 (211-1024.2)NANANABNPLiu et al,[@bib41] 2016156110500 (171-1689)463763 (628-23,382)NANANABNPMcCormack et al,[@bib42] 201637NA767.16±315.37NA1294.2±946.84NANANABNPMcLean et al,[@bib43] 20074031603±7089788±904NANANABNPPapanikolaou et al,[@bib44] 20144222732.4±122.5201099.5±133.880065/640.7BNPPost et al,[@bib45] 20089355119 (79.5-652)38672 (122-779.3)12176.3/52.70.65BNPRyoo et al,[@bib46] 2015290227469.1±761.8631156±1425.3NANANABNPSalim et al,[@bib47] 20154023326±199.117622.2±157.444994/790.88BNPShor et al,[@bib48] 20062113121.6±368.98201.2±301.6NANANABNPSturgess et al,[@bib49] 20102115448±60761289±115525483/600.76BNPTurner et al,[@bib50] 2011231160309±6147986±312NANANABNPYucel et al,[@bib24] 2008402013.72±12.9520254.78±308.6232.1100/950.99BNPZhang et al,[@bib51] 20127340550 (331-768)27738 (596-937)81648.2/87.50.71NT-proBNPBalcan et al,[@bib52] 201648331882±1652.291512,202±12,567.843736NA0.703NT-proBNPBalcan et al,[@bib53] 20151416937267210,428NANANANT-proBNPBrueckmann et al,[@bib54] 20055741493 (314-1126)161431 (712-1920)140050/90.20.68NT-proBNPCheng et al,[@bib55] 20154302942170±625.281365873.24±1768.37454268.8/69.50.62NT-proBNPGarcía Villalba et al,[@bib56] 20171741571112 (379-2570)176187 (1780-9949)1330NA0.793NT-proBNPGuaricci et al,[@bib57] 201540186586 (3281-9573)2212,743 (8352-14,289)1000NA0.73NT-proBNPJu et al,[@bib58] 2012100672902.23±5066.08333239±2687.31NANANANT-proBNPLandesberg et al,[@bib59] 20122621672275 (567-9426)9513,980 (5877-34,718)NANANANT-proBNPLi et al,[@bib60] 201410260360.4 (178.15-1204.5)42539 (314.5-785.4)NANANANT-proBNPMokart et al,[@bib61] 200751193414 (754-9005)267939 (4495-33,662)662486/770.87NT-proBNPPark et al,[@bib62] 201149184000 (1614-11,323)312819 (937-12,256)NA82/810.82NT-proBNPRoch et al[@bib25] 200539177856 (1291-12,972)2234,028 (11,735-49,320)13,60073/830.8NT-proBNPSasko et al,[@bib63] 201552241177±1854288623±34,296NANANANT-proBNPSekino et al,[@bib64] 201757448710 (1903-17,930)1334,820 (5432-65,122)NANA0.691NT-proBNPSturgess et al,[@bib27] 20102115841±81861801±185340083/400.67NT-proBNPVarpula et al,[@bib65] 20072541873479 (1102-9970)677908 (2658-20,855)709058/660.631NT-proBNPWang et al,[@bib66] 201638221839.14±1060.27163965.74±1462.65900NANANT-proBNPWang et al,[@bib67] 2015115381176.3±924.8772189.2±1673.5NANA0.719NT-proBNPZhang et al,[@bib68] 2013171104584 (321-875)671271 (851-1576)150089/870.89[^3]Figure 2Cumulative area under the receiver operating characteristic (ROC) curves for B-type natriuretic peptide (A) and N-terminal pro-B-type natriuretic peptide (B).

Discussion {#sec3}
==========

In this systematic review and meta-analysis of 36 studies and 3508 patients, we noted that (1) sepsis continues to be associated with a high mortality of 34.2%, (2) BNP and NT-proBNP are frequently elevated in patients with sepsis and are prognostic in this population, and (3) optimal cutoffs for BNP and NT-proBNP were calculated at 622 pg/mL and 4000 pg/mL for prediction of short-term mortality in patients with sepsis and septic shock. In prespecified subgroup analyses, identified BNP/NT-proBNP cutoffs had higher discrimination if specimens were obtained 24 hours or less after admission, in patients with severe sepsis/septic shock, in patients enrolled after 2010, and in studies performed in the United States and Europe.

The release of BNP and NT-proBNP in patients with sepsis is stimulated by myocytic stretch with ventricular dysfunction and proinflammatory molecules such as lipopolysaccharide, interleukin 1, C-reactive protein, and cardiotrophin 1 promoting BNP gene expression and release.[@bib37]^,^[@bib45]^,^[@bib48] Additionally, concomitant renal failure and processes of care such as catecholamine infusions and volume resuscitation lead to an elevation in BNP/NT-proBNP levels independent of ventricular function.[@bib2] Importantly, the timing of BNP release and therefore the optimal timing of measurement in this critically ill population remains debatable. As noted in this meta-analysis, there was wide variation in the timing of BNP measurement. Most studies measured it at admission or within the first 24 hours, which is reflective of contemporary clinical practice. It is important to note that in patients with sepsis, adequate fluid resuscitation and hemodynamic restoration can result in unmasking of left ventricular systolic dysfunction as manifested by a decrease in ejection fraction within the first 72 hours.[@bib4] Serial BNP testing may have greater clinical utility in prognostication for patients with sepsis than a 1-time measurement. Papanikolou et al[@bib44] recently reported that a persistently elevated BNP level of greater than 500 pg/mL was a better predictor of 28-day mortality than isolated BNP values. Inability to reduce BNP to less than 500 pg/mL predicted 28-day mortality with an AUROC of 0.74 (95% CI, 0.55-0.93; *P*=.03).[@bib44] In our meta-analysis, we were unable to assess the utility of serial BNP testing in mortality prediction because of high heterogeneity in the timing and frequency of sampling.

The use of natriuretic peptides to evaluate cardiac function in patients with sepsis has been studied extensively in multiple studies, including studies included in this meta-analysis. However, the evaluation of cardiac function with BNP has to be balanced against the potential confounding from respiratory pathology and renal failure. Pulmonary pathology such as acute respiratory distress syndrome and chronic obstructive pulmonary disease and interventions such as mechanical ventilation influence the BNP levels in this population.[@bib21]^,^[@bib30] As noted in this meta-analysis, studies variably exclude preexisting chronic kidney disease and inconsistently adjust for acute kidney injury in their analyses. In patients with sepsis, studies have found conflicting results regarding correlations between BNP and serum creatinine levels.[@bib25]^,^[@bib69] In an updated search incorporating studies from 2017-2019, there were no changes in the profile or outcome prediction using BNP/NT-proBNP. Further studies are needed to develop clinically relevant BNP cutoffs stratified by renal function in patients with sepsis to more usefully define ranges of BNP in these patients. Lastly, BNP/NT-proBNP needs to be contextualized to age and sex. Cutoffs based on age and sex have been suggested in primary care patients and heart failure populations but have not been validated in patients with sepsis at the current time.[@bib70]

It is important to note that unlike in patients with heart failure, there are no current cutoffs for BNP/NT-proBNP in patients with sepsis. Using a large sepsis population, we were able to develop cutoffs for mortality prediction in this population. It is important that biomarkers be considered in prognosticating modeling and early prediction of outcomes. A combination of early measurement of cardiac biomarkers has been postulated to differentiate Takotsubo cardiomyopathy from acute myocardial infarction.[@bib71] Similar paradigms might be useful in predicting the extent of reversible myocardial dysfunction and long-term risk for heart failure in patients with sepsis and septic cardiomyopathy.[@bib4] Furthermore, the use of cardiac biomarkers in risk scoring systems is worthy of further study. Khoury et al[@bib72] found the BNP level at admission to be more predictive of short-term mortality than the Sequential Organ Failure Assessment score. In contrast, Ryoo et al[@bib46] reported that the combination of BNP with the Sequential Organ Failure Assessment score resulted in better prognostication in patients with sepsis than either method alone. The use of cardiac biomarkers, including BNP/NT-proBNP, may be of incremental benefit in improving the accuracy of cardiovascular dysfunction in this population that may aid in personalized therapies for sepsis.[@bib6]^,^[@bib73] The BNP and NT-proBNP levels of 622 pg/mL and 4000 pg/mL noted in our study need further validation in carefully designed prospective studies. Given the subgroup analyses performed in our study, inclusion of pertinent enriched populations might aid in development of studies with a pragmatic sample size.

This study has important limitations. The selection of all types of sepsis can cause substantial heterogeneity in the assessment of clinical outcomes. Importantly, sepsis and septic shock may be fundamentally different in their etiology and clinical course. Furthermore, most studies did not systematically evaluate cardiac dysfunction. As we have reported previously, cardiac dysfunction and injury as measured by echocardiography or cardiac troponin T levels are associated with worse outcomes.[@bib1]^,^[@bib3], [@bib4], [@bib5]^,^[@bib7]^,^[@bib9] Fluid balance, prior heart failure, use of inotropic medications, and acute septic cardiomyopathy are closely associated with BNP release, and age, sex, and renal function are associated with varying BNP degradation.[@bib74] However, these factors were not systematically assessed in the individual studies included in our analyses, limiting the generalizability of our findings. Our study consisted primarily of observational studies, which have their own limitations. Observational studies are prone to confounding by indication and heterogeneity. This meta-analysis was performed in a study-level population, and thus, despite best attempts, crucial differences in patient characteristics across studies may have contributed to the results we observed. In addition, it is clear that natriuretic peptide assays vary substantially in their dynamic ranges. Thus, different assays may provide different numerical results in studies. Unfortunately, the data did not allow us to separate out those studies. It is clear, for this reason alone but likely for others as well, that a heterogeneity analysis would not have been productive.[@bib17]^,^[@bib75] Finally, this study evaluated short-term mortality only, with limited insight into long-term survival and functional recovery, both of which remain a challenge in patients with sepsis and cardiac dysfunction.[@bib4]

Conclusion {#sec4}
==========

In this hypothesis-generating meta-analysis of 3508 patients, BNP and NT-proBNP levels of 622 pg/mL and 4000 pg/mL were noted to predict short-term mortality with an AUROC of 0.766 and 0.787, respectively. Further dedicated research into the incorporation of these biomarkers into prognostic models and structured evaluation of cardiovascular dysfunction in patients with sepsis are needed to understand the clinical implications of these findings.
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[^1]: ACS = acute coronary syndrome; AKI = acute kidney injury; ARDS = acute respiratory distress syndrome; BNP = B-type natriuretic peptide; CAD = coronary artery disease; CHF = congestive heart failure; CKD = chronic kidney disease; CNS = central nervous system; COPD = chronic obstructive pulmonary disease; CP = cor pulmonale; DCM = dilated cardiomyopathy; echo = echocardiography; ED = emergency department; HTN = hypertension; ICH = intracranial hemorrhage; ICU = intensive care unit; IMV = invasive mechanical ventilation; LVEF = left ventricular ejection fraction; LVH = left ventricular hypertrophy; MI = myocardial infarction; NA = not available; NT-proBNP = N-terminal pro-B-type natriuretic peptide; PH = pulmonary hypertension; RWMA = regional wall motion abnormalities; TBI = traumatic brain injury; US = United States; VHD = valvular heart disease; VTE = venous thromboembolism.

[^2]: BNP = B-type natriuretic peptide; ED = emergency department; ICU = intensive care unit; IQR = interquartile range; NT-proBNP = N-terminal pro-B-type natriuretic peptide; SD = standard deviation.

[^3]: AUROC = area under receiver operating characteristic curve; BNP = B-type natriuretic peptide; IQR = interquartile range; NT-proBNP = N-terminal pro-B-type natriuretic peptide; Sn = sensitivity; Sp = specificity.
